Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Triiodothyronine × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 2 Medulloblastoma 1 Hypothyroidism 1 Goiter 1 Ependymoma 1 Breast Neoplasms 1

Interventions

Trastuzumab 301 Paclitaxel 256 Cyclophosphamide 250 Docetaxel 237 Capecitabine 175 Letrozole 163 Carboplatin 163 Doxorubicin 145 Fulvestrant 144 Bevacizumab 121 Anastrozole 105 Tamoxifen 100 exemestane 93 Vinorelbine 91 Epirubicin 90 pertuzumab 85 Gemcitabine 84 Lapatinib 80 Albumin-Bound Paclitaxel 74 Radiotherapy 71 pembrolizumab 70 palbociclib 64 130-nm albumin-bound paclitaxel 58 eribulin 56 Cisplatin 55 Everolimus 49 pyrotinib 44 Taxes 44 Goserelin 43 Neoadjuvant Therapy 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03787303 2022-05-13

B-TREUH

Aultman Health Foundation

Phase 2 Terminated

7 enrolled 14 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡